Washington Growth Strategies LLC Acquires New Shares in Thermo Fisher Scientific Inc. $TMO

Washington Growth Strategies LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 842 shares of the medical research company’s stock, valued at approximately $422,000.

A number of other hedge funds have also recently made changes to their positions in the company. Legacy Wealth Managment LLC ID increased its stake in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares during the period. Kilter Group LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $25,000. Allied Private Wealth LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $26,000. High Note Wealth LLC increased its position in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares during the period. Finally, Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $28,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on TMO. Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective on the stock. Evercore set a $570.00 target price on Thermo Fisher Scientific in a report on Monday, July 6th. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Royal Bank Of Canada lifted their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $612.75 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm’s fifty day simple moving average is $570.91 and its two-hundred day simple moving average is $515.10. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $647.00. The stock has a market capitalization of $226.56 billion, a P/E ratio of 32.96, a price-to-earnings-growth ratio of 2.59 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the business earned $4.28 EPS. The firm’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.11%.

Insider Activity at Thermo Fisher Scientific

In other news, CAO Joseph Holmes sold 420 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This trade represents a 12.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc Casper sold 275 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 73,768 shares of company stock worth $44,122,820. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.